急性冠状动脉综合征的抗凝治疗
Anticoagulant Therapy for Acute Coronary Syndromes.
作者信息
Onwordi Eunice Nc, Gamal Amr, Zaman Azfar
机构信息
Portsmouth Hospitals NHS Trust Portsmouth, UK.
Freeman Hospital and Newcastle University and Newcastle Upon Tyne Hospitals NHS Trust Newcastle, UK.
出版信息
Interv Cardiol. 2018 May;13(2):87-92. doi: 10.15420/icr.2017:26:1.
Abstract
Anticoagulation in conjunction with antiplatelet therapy is central to the management of acute coronary syndromes (ACS). When used effectively it is associated with a reduction in recurrent ischaemic events including myocardial infarction and stent thrombosis as well as a reduction in death. Effective ischaemic risk reduction whilst balancing bleeding risk remains a clinical challenge. This article reviews the current available evidence for anticoagulation in ACS and recommendations from the European Society of Cardiology.
摘要
抗凝治疗联合抗血小板治疗是急性冠脉综合征（ACS）管理的核心。有效使用时，它与复发性缺血事件（包括心肌梗死和支架血栓形成）的减少以及死亡风险的降低相关。在平衡出血风险的同时有效降低缺血风险仍然是一项临床挑战。本文回顾了目前关于ACS抗凝治疗的现有证据以及欧洲心脏病学会的建议。
相似文献
1
Anticoagulant Therapy for Acute Coronary Syndromes.急性冠状动脉综合征的抗凝治疗
Interv Cardiol. 2018 May;13(2):87-92. doi: 10.15420/icr.2017:26:1.
2
Cost effectiveness of anticoagulation in acute coronary syndromes.急性冠状动脉综合征中的抗凝治疗成本效益。
Pharmacoeconomics. 2012 Apr;30(4):303-21. doi: 10.2165/11589290-000000000-00000.
3
Comparative efficacy and safety of anticoagulant strategies for acute coronary syndromes. Comprehensive network meta-analysis of 42 randomised trials involving 117,353 patients.急性冠状动脉综合征抗凝策略的比较疗效和安全性。对42项涉及117353例患者的随机试验进行综合网络荟萃分析。
Thromb Haemost. 2015 Nov;114(5):933-44. doi: 10.1160/TH14-12-1066. Epub 2015 Jul 16.
4
Fondaparinux and acute coronary syndromes: update on the OASIS 5-6 studies.磺达肝癸钠与急性冠脉综合征：OASIS 5-6研究最新进展
Vasc Health Risk Manag. 2010 Apr 15;6:179-87. doi: 10.2147/vhrm.s6099.
5
Anticoagulant therapy in acute coronary syndromes.
Future Cardiol. 2007 May;3(3):301-8. doi: 10.2217/14796678.3.3.301.
6
[Use of parenteral anticoagulants in patients with coronary syndrome].
Medicina (B Aires). 2023;83(6):948-965.
7
Fondaparinux: A cornerstone drug in acute coronary syndromes.磺达肝癸钠：急性冠状动脉综合征的基石药物。
World J Cardiol. 2022 Jan 26;14(1):40-53. doi: 10.4330/wjc.v14.i1.40.
8
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in high-bleeding-risk patients with acute coronary syndrome in contemporary practice.比伐卢定与普通肝素在急性冠脉综合征高危出血风险患者行经皮冠状动脉介入治疗中的比较。
Biomed Pharmacother. 2020 Oct;130:110758. doi: 10.1016/j.biopha.2020.110758. Epub 2020 Sep 17.
9
Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with non-ST-segment-elevation acute coronary syndromes or stable ischemic heart disease: results from the Evaluation of Drug-Eluting Stents and Ischemic Events registry.肝素单药治疗或比伐卢定在非 ST 段抬高型急性冠脉综合征或稳定型缺血性心脏病患者经皮冠状动脉介入治疗中的应用：来自药物洗脱支架和缺血事件评估登记研究的结果。
Circ Cardiovasc Interv. 2014 Jun;7(3):365-73. doi: 10.1161/CIRCINTERVENTIONS.113.001126. Epub 2014 Apr 15.
引用本文的文献
1
Prescriber perceptions of the safety and efficacy of unfractionated heparin versus low molecular weight heparin in the acute treatment phase: a qualitative study.处方者对普通肝素与低分子肝素在急性治疗阶段安全性和有效性的认知：一项定性研究
J Pharm Policy Pract. 2024 Nov 19;17(1):2418367. doi: 10.1080/20523211.2024.2418367. eCollection 2024.
2
Friend or Foe: Factor XII Deficiency Discovered Incidentally during Management of NSTEMI.敌友难辨：非ST段抬高型心肌梗死治疗过程中偶然发现的凝血因子Ⅻ缺乏症
Case Rep Hematol. 2023 Jun 29;2023:5926340. doi: 10.1155/2023/5926340. eCollection 2023.
3
Clinical Decision Pathway for the Use of Fondaparinux in the Management of Acute Coronary Syndrome (ACS) in Hospitals with and Without Catheter Laboratories: An Expert Opinion from India.在有和没有导管实验室的医院中使用磺达肝癸钠管理急性冠状动脉综合征（ACS）的临床决策路径：来自印度的专家意见
Cardiol Ther. 2023 Jun;12(2):261-274. doi: 10.1007/s40119-023-00312-x. Epub 2023 Apr 12.
4
Association of Prolonged Emergency Department Length of Stay with Adverse Events in Patients with Non-ST-Elevation Acute Coronary Syndrome.非ST段抬高型急性冠状动脉综合征患者急诊科留观时间延长与不良事件的关联
Open Access Emerg Med. 2022 Mar 10;14:109-117. doi: 10.2147/OAEM.S353630. eCollection 2022.
5
Evaluation of Effectiveness and Tolerability of Fondaparinux in the Management of Symptomatic Acute Coronary Syndrome: A Real-World Evidence-Based Study on an Indian Population.磺达肝癸钠治疗有症状急性冠脉综合征的有效性和耐受性评估：一项基于印度人群的真实世界循证研究
Cardiol Ther. 2022 Mar;11(1):129-141. doi: 10.1007/s40119-022-00253-x. Epub 2022 Feb 9.
6
Fondaparinux: A cornerstone drug in acute coronary syndromes.磺达肝癸钠：急性冠状动脉综合征的基石药物。
World J Cardiol. 2022 Jan 26;14(1):40-53. doi: 10.4330/wjc.v14.i1.40.
7
Cost-Effectiveness and Cost-Utility Analysis of the Use of Clopidogrel and Pantoprazole in Comparison with Clopidogrel and Omeprazole for the Secondary Prevention of Myocardial Infarction in Iran.在伊朗，氯吡格雷与泮托拉唑联用相较于氯吡格雷与奥美拉唑联用用于心肌梗死二级预防的成本效益和成本效用分析。
J Res Pharm Pract. 2021 Aug 3;10(2):90-95. doi: 10.4103/jrpp.JRPP_21_22. eCollection 2021 Apr-Jun.
8
Focus on the Lymphatic Route to Optimize Drug Delivery in Cardiovascular Medicine.聚焦淋巴途径以优化心血管医学中的药物递送
Pharmaceutics. 2021 Aug 4;13(8):1200. doi: 10.3390/pharmaceutics13081200.
9
Systemic Review of Biodegradable Nanomaterials in Nanomedicine.纳米医学中可生物降解纳米材料的系统评价
Nanomaterials (Basel). 2020 Apr 1;10(4):656. doi: 10.3390/nano10040656.
本文引用的文献
1
Current Antithrombotic Therapy in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Interventions.接受经皮冠状动脉介入治疗的急性冠状动脉综合征患者的当前抗栓治疗
Interv Cardiol. 2014 Apr;9(2):94-101. doi: 10.15420/icr.2011.9.2.94.
2
Targeting thrombin long-term after an acute coronary syndrome: Opportunities and challenges.急性冠状动脉综合征后长期靶向凝血酶：机遇与挑战。
Vascul Pharmacol. 2016 Jun;81:1-14. doi: 10.1016/j.vph.2016.03.003. Epub 2016 Mar 16.
3
Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes.比伐卢定或普通肝素治疗急性冠脉综合征。
N Engl J Med. 2015 Sep 10;373(11):997-1009. doi: 10.1056/NEJMoa1507854. Epub 2015 Sep 1.
4
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).2015年欧洲心脏病学会（ESC）非持续性ST段抬高型急性冠脉综合征患者管理指南：欧洲心脏病学会（ESC）非持续性ST段抬高型急性冠脉综合征患者管理工作组
Eur Heart J. 2016 Jan 14;37(3):267-315. doi: 10.1093/eurheartj/ehv320. Epub 2015 Aug 29.
5
Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction.磺达肝癸钠与低分子肝素用于非 ST 段抬高型心肌梗死患者的临床结局比较。
JAMA. 2015 Feb 17;313(7):707-16. doi: 10.1001/jama.2015.517.
6
Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective.心肌梗死后患者的心血管风险：全国真实世界数据表明长期视角的重要性。
Eur Heart J. 2015 May 14;36(19):1163-70. doi: 10.1093/eurheartj/ehu505. Epub 2015 Jan 13.
7
Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial.普通肝素与比伐卢定在经皮冠状动脉介入治疗（HEAT-PPCI）中的应用：一项开放标签、单中心、随机对照试验。
Lancet. 2014 Nov 22;384(9957):1849-1858. doi: 10.1016/S0140-6736(14)60924-7. Epub 2014 Jul 4.
8
Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction).替奈普酶溶栓联合血管成形术与单独溶栓治疗急性心肌梗死的随机多中心临床试验
急性心肌梗死溶栓（TIMI）17 试验
急性 ST 段抬高型心肌梗死患者直接经皮冠状动脉介入治疗（直接 PCI）与溶栓后即刻补救性 PCI 随机临床试验
经皮冠状动脉介入治疗（PCI）后早期替罗非班对 ST 段抬高型心肌梗死患者的疗效和安全性的荟萃分析
J Am Coll Cardiol. 2014;63(1):15-20. doi: 10.1016/j.jacc.2013.09.027. Epub 2013 Oct 16.
9
Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial.非 ST 段抬高型急性冠脉综合征中用奥塔米沙班进行抗凝治疗和缺血事件：TAO 随机临床试验。
JAMA. 2013 Sep 18;310(11):1145-55. doi: 10.1001/jama.2013.277165.
10
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.ST段抬高型急性心肌梗死患者管理的欧洲心脏病学会指南
Eur Heart J. 2012 Oct;33(20):2569-619. doi: 10.1093/eurheartj/ehs215. Epub 2012 Aug 24.
Zotero 插件